Abstract 1544P
Background
Patients (pts) with advanced gastric/gastroesophageal junction cancer that progresses on chemotherapy have poor outcomes. We investigated the safety and efficacy of camrelizumab combined with albumin-bound paclitaxel and S-1 in first-line treatment of HER-2-negative advanced gastric/gastroesophageal junction cancer.
Methods
This study was a single-arm, open-label, phase II clinical study. Eligible pts were adults with histologically confirmed HER-2 -negative advanced gastric/ gastroesophageal junction cancer. Pts participating in this study were required to detect PD-L1 expression, MSI/MMR status, and EBV virus content. Pts received camrelizumab (200 mg, day 1), S-1 (60mg/m2 bid, days 1-14), and albumin-bound paclitaxel (125mg/m2, days 1, 8) every 3 weeks. The maintenance therapy of camrelizumab (200 mg, day 1, every 3 weeks) was given to pts who did not progress after 4-6 cycles of chemotherapy until disease progression or unacceptable toxicity. Response was assessed every 6 weeks in accordance with RECIST1.1. The primary endpoint was overall response rate (ORR), and secondary endpoints included safety profile, progression free survival (PFS), overall survival (OS), and disease control rate (DCR).
Results
Between December 2020 and March 2023, a total of 28 pts were enrolled in this study. Median age was 57.5 (range: 35-71) years, and most pts were male (75.0%). Among 21 pts who were evaluated, the ORR was 71.4% (15/21) and the DCR was 95.2% (20/21). The median PFS was 9.3 months (95% Cl: 7.0-11.6), the Median follow-up time was 14.3 months (95% Cl: 9.9-18.7), and the one-year survival rate was 85.7%. The most common treatment-related adverse events of grade 3 or 4 included neutropenia (22.2%), leukopenia (22.2%), erythra (3.7%). There were no treatment-related deaths.
Conclusions
Camrelizumab plus albumin-bound paclitaxel and S-1 demonstrated promising activity and manageable safety in first-line treatment of HER-2- negative advanced gastric/gastroesophageal junction cancer.
Clinical trial identification
NCT04675866.
Editorial acknowledgement
Legal entity responsible for the study
Henan Cancer Hospital.
Funding
Jiangsu Hengrui Pharmaceutical Co. LTD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1489P - To investigate the differences in efficacy between immunotherapy and combined immunotherapy in elderly patients with non-small cell lung cancer
Presenter: Ye Mao
Session: Poster session 21
1490P - Removal of TNF-Rs frees TNF-α’s anticancer activity alone or in combination chemo- or immunotherapy in advanced NSCLC
Presenter: Mustafa Bozkurt
Session: Poster session 21
1491P - PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients
Presenter: Jeongmin Seo
Session: Poster session 21
1493P - A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
Presenter: Tomasz Jankowski
Session: Poster session 21
1495P - Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
Presenter: Ana Baramidze
Session: Poster session 21
1496P - Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Paul Takam Kamga
Session: Poster session 21
1497P - Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in untreated advanced non-small-cell lung cancer
Presenter: Yawen Bin
Session: Poster session 21